Prodose Inc. has strategically partnered with SHPL (Softgel Healthcare Pvt. Ltd.), a key member of the renowned Madras Pharma Group, to anchor its bulk manufacturing and sourcing operations in India.
Archives: Timeline Stories
Timeline Post Type Description
Facility Expansion in New York
Spirit expanded its manufacturing footprint by enhancing its New York facility, scaling up to approximately 115,000 square feet. This move aimed to boost production capacity and improve supply chain efficiency for its growing OTC and nutraceutical portfolio.
First U.S. API Sales and India R&D Expansion
In 2018, Spirit achieved a major milestone by selling its first API product in the U.S. market. That same year, the company expanded its capabilities by establishing a dedicated R&D facility in India to develop finished solid oral dosage forms.
Founding of Spirit Pharmaceuticals
Spirit Pharmaceuticals was founded in 2003 in Philadelphia, PA. Starting with a team of just five, the company initially focused on importing bulk active pharmaceutical ingredients (APIs) and raw materials from India to the U.S. market.